Dale RG - Search Results

1

Wessels BW, Dale RG, Cremonesi M, Meredith RF, Green AJ, Brill B, Bolch WE, Sgouros G, Thomas SR. Wessels BW, et al. Among authors: dale rg. Cancer Biother Radiopharm. 2010 Oct;25(5):597-9. doi: 10.1089/cbr.2010.0867. Epub 2010 Sep 28. Cancer Biother Radiopharm. 2010. PMID: 20874486 No abstract available.

2

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. Wessels BW, et al. Among authors: dale rg. J Nucl Med. 2008 Nov;49(11):1884-99. doi: 10.2967/jnumed.108.053173. Epub 2008 Oct 16. J Nucl Med. 2008. PMID: 18927342 Free article.

3

The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumor xenograft model.

Pedley RB, Dale R, Boden JA, Begent RH, Keep PA, Green AJ. Pedley RB, et al. Int J Cancer. 1989 Apr 15;43(4):713-8. doi: 10.1002/ijc.2910430429. Int J Cancer. 1989. PMID: 2539334

4

Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.

Begent RH, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA, Adam T, Dale RG, Glaser MG. Begent RH, et al. Among authors: dale rg. Br J Cancer. 1989 Sep;60(3):406-12. doi: 10.1038/bjc.1989.295. Br J Cancer. 1989. PMID: 2789951 Free PMC article.

5

Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

Ledermann JA, Begent RH, Bagshawe KD, Riggs SJ, Searle F, Glaser MG, Green AJ, Dale RG. Ledermann JA, et al. Among authors: dale rg. Br J Cancer. 1988 Nov;58(5):654-7. doi: 10.1038/bjc.1988.279. Br J Cancer. 1988. PMID: 3265333 Free PMC article.

6

The radiobiology of conventional radiotherapy and its application to radionuclide therapy.

Dale R, Carabe-Fernandez A. Dale R, et al. Cancer Biother Radiopharm. 2005 Feb;20(1):47-51. doi: 10.1089/cbr.2005.20.47. Cancer Biother Radiopharm. 2005. PMID: 15778580

7

A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.

Abou-Jaoudé W, Dale R. Abou-Jaoudé W, et al. Cancer Biother Radiopharm. 2004 Jun;19(3):308-21. doi: 10.1089/1084978041425089. Cancer Biother Radiopharm. 2004. PMID: 15285877

8

Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.

Dale R. Dale R. Cancer Biother Radiopharm. 2004 Jun;19(3):363-70. doi: 10.1089/1084978041425070. Cancer Biother Radiopharm. 2004. PMID: 15285884 Review.

9

Use of second antibody in radioimmunotherapy.

Begent RH, Bagshawe KD, Pedley RB, Searle F, Ledermann JA, Green AJ, Keep PA, Chester KA, Glaser MG, Dale RG. Begent RH, et al. Among authors: dale rg. NCI Monogr. 1987;(3):59-61. NCI Monogr. 1987. PMID: 3493442

10

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.

Pedley RB, Boden JA, Boden R, Dale R, Begent RH. Pedley RB, et al. Br J Cancer. 1993 Jul;68(1):69-73. doi: 10.1038/bjc.1993.288. Br J Cancer. 1993. PMID: 8318423 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page